In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Angiotensin Converting Enzyme Inhibitors in Cardiovascular Disease (ESC Expert Consensus Document on)

ESC Clinical Practice Guidelines

Coronary Artery Disease (Chronic)
Pharmacology and Pharmacotherapy
Cardiovascular Pharmacotherapy
Guidelines version available to download
Published in 2004
Reference European Heart Journal (2004) 25, 1454–1470; doi:10.1016/j.ehj.2004.06.003
Table of contents: Full Text (ESC Clinical Practice Guidelines)


  • Definition
  • ACE-inhibitor classification
  • Pharmacokinetic profile
  • Mechanism of action
  • Effects of ACE-inhibitors: Haemodynamic effects, Neurohormonal effects, Antiproliferative effects, Renal effects, Other effects, Effects on fibrinolytic balance
  • Side effects
  • Contraindications
  • Drug interactions
  • Dosing

Clinical efficacy and practical use

  • Heart failure: Target dose, ACE-I compared with angiotensin, receptor blockers
  • Asymptomatic left ventricular systolic dysfunction, Diastolic failure
  • Acute myocardial infarction
  • Hypertension
  • Secondary prevention and high-risk of cardiovascular disease
  • Prevention of sudden cardiac death